Jeremy T. Brock Net Worth

The estimated Net Worth of Jeremy T. Brock is at least $1.77 Million dollars as of 21 May 2020. Jeremy Brock owns over 48,000 units of Electromed stock worth over $1,772,820 and over the last 12 years Jeremy sold ELMD stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Jeremy Brock ELMD stock SEC Form 4 insiders trading

Jeremy has made over 1 trades of the Electromed stock since 2020, according to the Form 4 filled with the SEC. Most recently Jeremy exercised 48,000 units of ELMD stock worth $90,240 on 21 May 2020.

The largest trade Jeremy's ever made was exercising 48,000 units of Electromed stock on 21 May 2020 worth over $90,240. On average, Jeremy trades about 4,364 units every 0 days since 2012. As of 21 May 2020 Jeremy still owns at least 100,500 units of Electromed stock.

You can see the complete history of Jeremy Brock stock trades at the bottom of the page.

What's Jeremy Brock's mailing address?

Jeremy's mailing address filed with the SEC is 500 SIXTH STREET NW, , NEW PRAGUE, MN, 56071.

Insiders trading at Electromed

Over the last 14 years, insiders at Electromed have traded over $2,585,226 worth of Electromed stock and bought 684,801 units worth $2,582,707 . The most active insiders traders include Oak Partners, Llc Red, Stephen H. Craney und Kathleen Skarvan. On average, Electromed executives and independent directors trade stock every 84 days with the average trade being worth of $358,798. The most recent stock trade was executed by James L. Cunniff on 1 March 2024, trading 9,000 units of ELMD stock currently worth $137,250.

What does Electromed do?

electromed, inc. is a minnesota-based company (nyse mkt: elmd) and the innovative leader in the development, manufacture, and worldwide sales of the smartvest® airway clearance system. the patented system uses high frequency chest wall oscillation (hfcwo), a better-tolerated alternative to chest physiotherapy (cpt), to deliver vigorous, yet comfortable airway clearance treatment for patients battling the consequences of retained secretions. hfcwo has been clinically proven to clear the lungs of excess mucus, improve and reduce lung infections for individuals suffering from various conditions including atelectasis, copd, bronchiectasis, neuromuscular diseases, and cystic fibrosis. electromed, inc. is accredited by the joint commission and is iso 13485:2003 and iso 9001:2008 certified.

Complete history of Jeremy Brock stock trades at Electromed

Electromed executives and stock owners

Electromed executives and other stock owners filed with the SEC include:

• Kathleen Skarvan,
  President, Chief Executive Officer, Director
• Kathleen S. Skarvan,
  CEO, Pres & Director
• Michael Joseph MacCourt,
  Chief Fin. Officer
• Stephen Craney,
  Independent Chairman of the Board
• Michael MacCourt,
  Chief Financial Officer
• Stan Erickson,
  Independent Director
• Gregory Fluet,
  Independent Director
• Lee Jones,
  Independent Director
• George Winn,
  Independent Director
• Andrea Walsh,
  Independent Director
• Kalle Ahl,
  IR Contact Officer
• Kathryn Thompson,
  VP of Reimbursement
• William J. George,
  Sec.
• Bud Reeves,
  VP of Sales
• William Eckles,
  Director
• Jeremy T. Brock,
  Chief Financial Officer
• Oak Partners, Llc Red,
  10% owner
• John L Erb,
  Director
• Craig N. Hansen,
  Director
• James J. Cassidy,
  Chief Operating Officer
• Darrel L Kloeckner,
  Director
• Terry M. Belford,
  Chief Financial Officer
• Thomas M. Hagedorn,
  Director
• Robert D. Hansen,
  Chief Executive Officer
• Andrew Summers,
  Director
• Bradley M. Nagel,
  Chief Financial Officer
• Christopher G. Holland,
  Chief Commercial Officer
• Kathleen A Tune,
  Director
• Joseph L. Galatowitsch,
  Director
• Michelle C. Wirtz,
  Chief Financial Officer
• James L. Cunniff,
  CEO and President